^
    BIOMARKER:

    HER-2 positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    HER-2 positive
    Gastric Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    Curr Probl Cancer - 5 days
    HER-2 positive
    Gastric Cancer
    nivolumab
    Resistant: B - Late Trials
    Cancer Med - 1 week
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab
    Sensitive: A1 - Approval
    N Z Med J - 1 week
    HER-2 positive
    Salivary Gland Cancer
    trastuzumab
    Sensitive: A1 - Approval
    Chugai Press Release - 1 week
    HER-2 positive
    HER2 Positive Breast Cancer
    KN026
    Sensitive: C2 – Inclusion Criteria
    Clin Cancer Res - 1 week
    HER-2 positive
    CRC
    HER2-targeted CAR-T immunotherapy
    Sensitive: D – Preclinical
    Cell Death Dis - 1 week
    HER-2 positive
    HER2 Positive Breast Cancer
    ado-trastuzumab emtansine
    Sensitive: A1 - Approval
    SABCS 2021 - 2 weeks
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + pertuzumab
    Sensitive: A1 - Approval
    Future Oncol - 3 weeks
    HER-2 positive
    Gastric Cancer
    trastuzumab + ramucirumab + ALX148
    Sensitive: C3 – Early Trials
    SITC 2021 - 3 weeks
    HER-2 positive
    HER2 Positive Breast Cancer
    HER2-targeted CAR-T immunotherapy
    Sensitive: D – Preclinical
    SITC 2021 - 3 weeks
    HER-2 positive
    HER2 Positive Breast Cancer
    AB-201
    Sensitive: D – Preclinical
    SITC 2021 - 3 weeks
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + tucatinib
    Sensitive: A1 - Approval
    HER-2 positive
    HER2 Positive Breast Cancer
    margetuximab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    HER-2 positive
    HER2 Positive Breast Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    pembrolizumab + trastuzumab
    Sensitive: A1 - Approval
    HER-2 positive
    HER2 Positive Breast Cancer
    pertuzumab/trastuzumab/hyaluronidase-zzxf
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    HER2 Positive Breast Cancer
    neratinib
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    HER2 Positive Breast Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab + trastuzumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    trastuzumab
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    TCHP
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    TCH
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + lapatinib
    Sensitive: A2 - Guideline
    HER-2 positive
    GastroEsophageal Cancer
    trastuzumab
    Sensitive: A2 - Guideline
    HER-2 positive
    Esophageal Adenocarcinoma
    trastuzumab
    Sensitive: A2 - Guideline
    HER-2 positive
    Endometrial Cancer
    trastuzumab
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    pertuzumab
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    HER2 inhibitor
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    AC-TH
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    lapatinib
    Sensitive: A2 - Guideline
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    HER2 inhibitor
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    AC-THP
    Sensitive: A2 - Guideline
    HER-2 positive
    HER2 Positive Breast Cancer
    TH
    Sensitive: A2 - Guideline
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab + pertuzumab
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    pyrotinib
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + pyrotinib
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: B - Late Trials
    HER-2 positive
    Gastric Cancer
    trastuzumab + pertuzumab
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    ado-trastuzumab emtansine + pertuzumab
    Sensitive: B - Late Trials
    HER-2 positive
    Urothelial Cancer
    disitamab vedotin
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    SYD985
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    TX05 (trastuzumab biosimilar)
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    EG12014 (trastuzumab biosimilar)
    Sensitive: B - Late Trials
    HER-2 positive
    HER2 Positive Breast Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: B - Late Trials
    HER-2 positive
    Small Cell Lung Cancer
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 positive
    Endometrial Adenocarcinoma
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 positive
    NSCLC
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 positive
    CRC
    fam-trastuzumab deruxtecan-nxki
    Sensitive: C1 - Off-label
    HER-2 positive
    GastroEsophageal Cancer
    pembrolizumab + trastuzumab
    Sensitive: C1 - Off-label
    HER-2 positive
    Colon Cancer
    ado-trastuzumab emtansine
    Sensitive: C1 - Off-label
    HER-2 positive
    Esophageal Adenocarcinoma
    trastuzumab + pertuzumab
    Sensitive: C1 - Off-label
    HER-2 positive
    Solid Tumor
    neratinib
    Resistant: C1 - Off-label
    HER-2 positive
    Gastric Cancer
    ado-trastuzumab emtansine
    Sensitive: C1 - Off-label
    HER-2 positive
    Esophageal Squamous Cell Carcinoma
    trastuzumab
    Sensitive: C1 - Off-label
    HER-2 positive
    Biliary Tract Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: C1 - Off-label
    HER-2 positive
    Biliary Tract Cancer
    trastuzumab + pertuzumab
    Sensitive: C1 - Off-label
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    paclitaxel
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Lung Cancer
    pyrotinib
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Gastric Cancer
    pyrotinib
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    margetuximab + MGD013
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    PRS-343
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Gastric Cancer
    PRS-343
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    PRS-343
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    bevacizumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    epirubicin
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    paclitaxel
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    HM 78136B
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Gastric Adenocarcinoma
    pembrolizumab + margetuximab
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Solid Tumor
    KN046 + KN026
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    neratinib + ado-trastuzumab emtansine
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    CRC
    pyrotinib
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Gastric Cancer
    pyrotinib + SHR6390
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    GastroEsophageal Cancer
    pembrolizumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    afatinib
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    A166
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    CRC
    A166
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    pembrolizumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    disitamab vedotin
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    ARX788
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + copanlisib
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    ASLAN001
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    BAT8001
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    albumin-bound paclitaxel
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    palbociclib + ado-trastuzumab emtansine
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Solid Tumor
    disitamab vedotin
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Solid Tumor
    pyrotinib + SHR6390
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Gastric Cancer
    trastuzumab + ramucirumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Gastric Cancer
    rivoceranib
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + atezolizumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    HER2 Positive Breast Cancer
    HP + eribulin mesylate
    Sensitive: C2 – Inclusion Criteria
    HER-2 positive
    Gastric Cancer
    MRG002
    Sensitive: C2 – Inclusion Criteria